Basic epidemiology and immunopathology of RSV in children.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and epidemiology without systematic review methodology
PubMed 12531081 · doi:10.1053/prrv.2000.0050
What was done
This narrative review synthesized epidemiological data and immunopathological mechanisms of respiratory syncytial virus (RSV) infection in infants and young children, focusing on clinical burden, risk groups, and immune response dynamics.
What was found
Most children contract RSV by age 2. In the UK, annual epidemics lead to approximately 20,000 infant hospitalizations, representing about 3% of the birth cohort. Severe disease risk factors include young age, prematurity, chronic lung or cardiac disease, and immunodeficiency. Humoral immunity is incomplete and short-lived, failing to prevent reinfection even with neutralizing antibodies present, though reinfections are typically less severe. Cellular immunity is required to limit severity; infection induces an RSV-specific T-lymphocyte response with cytokine release, balancing protective clearance against immunopathological tissue damage.
Why it matters
It summarizes the major epidemiological footprint of pediatric RSV and explains why vaccines or treatments must balance protective immunity against disease-enhancing cellular responses.
Limits
This is a narrative review with no systematic search criteria, meta-analysis, or primary clinical trial data provided in the abstract. No statistical effect sizes, variances, or study sample sizes are reported.
Cited by
- supports Respiratory syncytial virus (RSV) infects the respiratory tract of most children by 2 years of age.